See the DrugPatentWatch profile for tigecycline

Yes, tigecycline, a broad-spectrum antibiotic, has been associated with liver damage in certain populations. According to the Tigecycline (Tygacil) Prescribing Information by Pfizer Laboratories Div Pfizer Inc. [1], elevations in liver function tests and hepatic dysfunction have been observed in patients treated with tigecycline.

A study published in the Journal of Clinical Pharmacy and Therapeutics [2] analyzed the adverse effects of tigecycline and reported that elevated liver enzymes and hepatotoxicity were among the most common adverse effects. The study concluded that tigecycline should be used with caution in patients with hepatic impairment.

Moreover, DrugPatentWatch.com [3] states that tigecycline has a black box warning for increased risk of death compared to other antibiotics and also mentions that it may cause liver damage.

In conclusion, tigecycline can cause liver damage in certain populations, particularly those with hepatic impairment or those receiving prolonged treatment. Healthcare professionals should exercise caution when prescribing tigecycline and closely monitor liver function in patients receiving the drug.

Sources:
[1] Pfizer Laboratories Div Pfizer Inc. (2018). Tigecycline (Tygacil) Prescribing Information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021867s022lbl.pdf>
[2] Giamarellos-Bourboulis, E. J., et al. (2012). Adverse events of tigecycline: a systematic review and meta-analysis. Journal of Clinical Pharmacy and Therapeutics, 37(3), 235-243. <https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2710.2012.01351.x>
[3] DrugPatentWatch.com. (2021). Tigecycline. <https://www.drugpatentwatch.com/drugs/tigecycline>